PMID- 36856069
OWN - NLM
STAT- MEDLINE
DCOM- 20230308
LR  - 20230327
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 23
IP  - 3
DP  - 2023 Mar
TI  - Clinical efficacy and safety of bispecific antibodies for the treatment of solid 
      tumors: a systematic review and meta-analysis.
PG  - 307-318
LID - 10.1080/14737140.2023.2183847 [doi]
AB  - INTRODUCTION: Immunotherapy is a promising and progressing treatment approach for 
      cancer. Bispecific antibodies (BsAbs) are antibody constructs that can bind to 
      two different epitopes. The dual-specificity of BsAbs improves their efficacy 
      compared to monoclonal antibodies. AREAS COVERED: Although BsAbs have achieved 
      excellent therapeutic effects in hematologic cancers, no systematic review with 
      meta-analysis evaluated their efficacy in solid tumors. In the present systematic 
      review and meta-analysis, we aimed to establish the clinical efficacy and safety 
      of BsAbs in solid tumors. EXPERT OPINION: BsAbs are not associated with 
      significantly better safety or efficacy outcomes than conventional therapies. 
      BsAb was not associated with improvement in overall survival (OS), 
      progression-free survival (PFS), objective response rate (ORR), and disease 
      control rate (DCR). However, BsAb increased the rate of stable disease (SD) 
      significantly. Also, BsAb substantially increased the OS and PFS and resulted in 
      a higher frequency of DCR for uveal melanoma. Furthermore, the safety analysis 
      showed no obvious difference in the rate of any adverse events (AEs), grade >/=3 
      AEs, serious AEs, and AEs leading to treatment discontinuation in the 
      intervention group compared to controls. Further high-quality randomized 
      controlled trials on BsAbs in solid tumors are highly recommended.
FAU - Nejadghaderi, Seyed Aria
AU  - Nejadghaderi SA
AD  - Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific 
      Education and Research Network (USERN), Tehran, Iran.
AD  - Cancer Immunology Project (CIP), Universal Scientific Education and Research 
      Network (USERN), Tehran, Iran.
AD  - School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Balibegloo, Maryam
AU  - Balibegloo M
AD  - Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific 
      Education and Research Network (USERN), Tehran, Iran.
AD  - Cancer Immunology Project (CIP), Universal Scientific Education and Research 
      Network (USERN), Tehran, Iran.
AD  - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal 
      Scientific Education and Research Network (USERN), Tehran, Iran.
FAU - Noori, Maryam
AU  - Noori M
AD  - Student Research Committee, School of Medicine, Iran University of Medical 
      Sciences, Tehran, Iran.
AD  - Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Fayyaz, Farimah
AU  - Fayyaz F
AD  - Cancer Immunology Project (CIP), Universal Scientific Education and Research 
      Network (USERN), Tehran, Iran.
AD  - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal 
      Scientific Education and Research Network (USERN), Tehran, Iran.
AD  - Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.
FAU - Saghazadeh, Amene
AU  - Saghazadeh A
AD  - Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific 
      Education and Research Network (USERN), Tehran, Iran.
AD  - Research Center for Immunodeficiencies, Children's Medical Center, Tehran 
      University of Medical Sciences, Tehran, Iran.
FAU - Rezaei, Nima
AU  - Rezaei N
AD  - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal 
      Scientific Education and Research Network (USERN), Tehran, Iran.
AD  - Research Center for Immunodeficiencies, Children's Medical Center, Tehran 
      University of Medical Sciences, Tehran, Iran.
AD  - Department of Immunology, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230301
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Antibodies, Bispecific)
SB  - IM
MH  - Humans
MH  - *Antibodies, Bispecific/adverse effects
MH  - Treatment Outcome
MH  - *Melanoma
MH  - Immunotherapy
MH  - Progression-Free Survival
OTO - NOTNLM
OT  - Bispecific antibody
OT  - Meta-analysis
OT  - efficacy
OT  - immunotherapy
OT  - safety
OT  - solid tumors
OT  - systematic review
EDAT- 2023/03/02 06:00
MHDA- 2023/03/09 06:00
CRDT- 2023/03/01 05:33
PHST- 2023/03/02 06:00 [pubmed]
PHST- 2023/03/09 06:00 [medline]
PHST- 2023/03/01 05:33 [entrez]
AID - 10.1080/14737140.2023.2183847 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2023 Mar;23(3):307-318. doi: 
      10.1080/14737140.2023.2183847. Epub 2023 Mar 1.